Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal Onset Epilepsy

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal Onset Epilepsy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs XEN 1101 (Primary)
  • Indications Partial epilepsies; Seizures
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Xenon Pharmaceuticals
  • Most Recent Events

    • 07 Feb 2019 Status changed from planning to not yet recruiting.
    • 06 Feb 2019 Status changed from not yet recruiting to recruiting.
    • 06 Jan 2019 According to a Xenon Pharmaceuticals media release, depending upon the rate of enrollment, top-line results are anticipated in the second half of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top